Lead Development Representative

Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.

A meaningful gift marks a milestone moment at Rompa CZ. Rompa now has a lasting reminder of the opening ceremony for its new Class 7 cleanroom facility in the Czech Republic, in the form of a thoughtful symbolic gift from its customer, the biotechnology company Revvity. This special artwork connects the event to the wider story of Life Sciences research, and was presented by Revvity's Managing Director, Jochem Bruggeman, to Marcos Valladolid, Rompa's COO. The story behind the artwork. The art was created using Revvity's own instruments and depicts HeLa cells, which hold a unique place in biomedical research. They were the first human cells successfully grown continuously in a laboratory and remain one of the most widely used cell lines in science today. Originally taken from Henrietta Lacks in 1951, HeLa cells have contributed to thousands of scientific breakthroughs over more than 75 years of research. They have played an important role in areas including vaccine development, cancer research, virology, drug screening, gene mapping and many other fields of biomedical science. The story of HeLa cells is also an important reminder of the ethical responsibilities that come with scientific progress. Henrietta Lacks' cells were used without her knowledge or consent, raising questions about patient rights, informed consent and the use of biological materials in research. Those discussions continue to influence how biomedical research is conducted today. Celebrating a long-standing partnership with Revvity. For Rompa, the present is a symbol of the partnership between its two companies and of the Life Sciences work now taking place inside the new cleanroom. The gift also marks Rompa's longstanding partnership with Revvity, whose products are among the first being produced in the new ISO Class 7 cleanroom at Rompa CZ. This made the opening ceremony not only a celebration of a new facility, but also a celebration of the collaboration, trust and shared commitment that helped bring the project to life. The cleanroom is designed to support multiple integrated production lines, including automated manufacturing solutions for microplate production. It enables Rompa to support customers with demanding applications in healthcare, diagnostics and other highly regulated Life Sciences markets. Rompa Group is grateful to Revvity for such a thoughtful gesture, and to everyone who joined Rompa Group to mark this important moment for Rompa CZ. As the artwork reminds Rompa Group, progress in Life Sciences depends on precision, partnership and respect for the scientific work that helps improve lives. Rompa Group is proud that its new cleanroom will play a part in supporting that work for years to come.

Revvity developing large scale latent tuberculosis test. * July 24, 2026 Revvity has announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB testing for large-volume clinical laboratories, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and broader public health programs. It is crucial for laboratories to deliver accurate results upon initial testing, while managing a high volume of samples to support timely treatment and improved patient outcomes. Building on the success of the Auto-Pure 2400 liquid handler, (pictured) the T-SPOT A201 platform is engineered to meet the throughput requirements of large-scale testing environments, strengthening the Revvity's automation portfolio and its ability to support laboratories across a range of throughput needs. It can process up to 384 samples per instrument in an 8-hour shift, with 45 seconds per sample of hands-on time - the lowest of any T-SPOT automation solution. The platform aims to ensure that these laboratories benefit from the scalability and workflow advantages associated with automated T-SPOT.TB testing. "The T-SPOT A201 automation platform represents a significant step forward in making the benefits of T-SPOT.TB testing accessible at scale," said Steven Hart, Vice President and General Manager of Infectious Disease Diagnostics at Revvity. "Our development program is focused on delivering a solution that gives high-volume clinical laboratories the performance, workflow efficiency, and competitive economics they need." The T-SPOT A201 platform is currently under development and targeted for launch in the second half of 2027, subject to regulatory approval.